Results 11 to 20 of about 90,511 (304)

Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma

Journal of Immunology Research, 2022
Thyroid dysfunction (TD) induced by programmed death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) has been widely reported.
Ying Chen, Lei Zhuang, Danhong Zhang, Xianghui Du, Liming Sheng   +4 more
doaj   +1 more source

Survival benefit of thoracic radiotherapy plus EGFR-TKIs in patients with non-oligometastatic advanced non-small-cell lung cancer: a single-center retrospective study

Therapeutic Advances in Medical Oncology, 2023
Objectives: The study aims to evaluate the efficacy and safety of thoracic radiotherapy in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-treated patients with stage IV non-small-cell lung cancer (NSCLC).
Fangyuan Zhou, You Qin, Xixi Liu, Jing Huang, Bian Wu, Zhanjie Zhang, Zhongyuan Yin, Jinsong Yang, Sheng Zhang, Ke Jiang, Kunyu Yang   +10 more
doaj   +1 more source

E3 Ubiquitin Ligase CHIP Inhibits the Interaction between Hsp90β and MAST1 to Repress Radiation Resistance in Non-Small-Cell Lung Cancer Stem Cells

Stem Cells International, 2022
The radiation resistance of cancer stem cells poses a critical obstacle for management of non-small-cell lung cancer (NSCLC). It is interesting to note that E3 ubiquitin ligase CHIP is involved in radiation resistance and stemness phenotypes in NSCLC ...
Bo Tan, Jingwei Zhang, Wen Wang, Haibo Ma, Yuanyuan Yang   +4 more
doaj   +1 more source

Coconut atrium following thoracic radiotherapy [PDF]

Heart, 2004
A 45 year old man who had previously undergone curative surgery and radiotherapy for a thoracic neuroblastoma in childhood was referred for assessment of breathlessness and exertional dizziness. A high resolution thoracic computed tomographic scan demonstrated patchy pulmonary fibrosis and incidentally revealed the presence of localised extensive ...
N P, Jenkins, N H, Brooks, M, Greaves
openaire   +2 more sources

Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series

Frontiers in Oncology, 2023
Pseudoprogression is rarely mentioned after radiotherapy except for central nervous system tumors. With the widespread of immunotherapy, the incidence of pseudoprogression of thoracic tumor after radiotherapy is increasing.
Yongbo Xiang, Wei Tang, Jianyang Wang, Zhijie Wang, Nan Bi   +4 more
doaj   +1 more source

Impact of thoracic tumor radiotherapy on survival in non‐small‐cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study

Cancer Medicine, 2023
Background EGFR‐mutant (EGFR‐M) and ALK‐positive (ALK‐P)are common in malignant pleural effusion (MPE) with metastatic non‐small‐cell lung cancer (NSCLC) (MPE‐NSCLC). The impact of thoracic tumor radiotherapy on survival in such patients remains unclear.
Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Haijie Jin, Huiqin Li, Bing Lu   +8 more
doaj   +1 more source

Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy

Radiation Oncology, 2021
Background The exact rate and relevant risk factors of radiation pneumonitis (RP) for non-small-cell cancer (NSCLC) patients treated with the combination of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and thoracic radiotherapy
Wenxiao Jia, Qianqian Gao, Min Wang, Ji Li, Wang Jing, Jinming Yu, Hui Zhu   +6 more
doaj   +1 more source

Assessment of short-term effects of thoracic radiotherapy on the cardiovascular parasympathetic and sympathetic nervous systems

Frontiers in Neuroscience, 2023
BackgroundPrior research suggests that cardiovascular autonomic dysfunction might be an early marker of cardiotoxicity induced by antitumor treatment and act as an early predictor of cardiovascular disease-related morbidity and mortality.
Shuang Wu, Shuang Wu, Weizheng Guan, Weizheng Guan, Huan Zhao, Huan Zhao, Guangqiao Li, Guangqiao Li, Yufu Zhou, Bo Shi, Bo Shi, Xiaochun Zhang, Xiaochun Zhang   +12 more
doaj   +1 more source

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer

Clinical and Translational Radiation Oncology, 2021
Background: The RAS/RAF/MEK/ERK signalling pathway has a pivotal role in cancer proliferation and modulating treatment response. Selumetinib inhibits MEK and enhances effects of radiotherapy in preclinical studies.
K. Haslett, P. Koh, A. Hudson, W.D. Ryder, S. Falk, D. Mullan, B. Taylor, R. Califano, F. Blackhall, C. Faivre-Finn   +9 more
doaj   +1 more source

Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting [PDF]

, 2019
The management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of ...
Girard, N, Grassino, M, Imbimbo, M, Maury, J, Vitale, F   +4 more
core   +1 more source